A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

Completed · Phase 1 · Has a placebo group

Conditions studied: Obesity

In brief

Single ascending dose of HM15211 in healthy obese subjects.

Key facts

Study ID

NCT03374241

Run by

Hanmi Pharmaceutical Company Limited

People needed

41

Starts

2018-04-04

Expected to finish

2018-09-14

Last updated by the study team

2025-02-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Female subjects must be non-pregnant and non-lactating

You may not qualify if…

• Participation in an investigational study within 30 days prior to dosing

Where it is running

• Hanmi Investigative Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.